- Home
- PANW vs SNY Comparison
PANW vs SNY Comparison
Compare PANW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PANW | SNY |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.9B | 116.8B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | PANW | SNY |
|---|---|---|
| Price | $155.83 | $46.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 39 | 6 |
| Target Price | ★ $216.83 | $61.50 |
| AVG Volume (30 Days) | ★ 14.4M | 4.3M |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.35% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.07 | N/A |
| Revenue | ★ $2,273,100,000.00 | N/A |
| Revenue This Year | $16.66 | $2.62 |
| Revenue Next Year | $13.52 | $6.38 |
| P/E Ratio | $140.18 | ★ $6.14 |
| Revenue Growth | ★ 29.04 | N/A |
| 52 Week Low | $139.57 | $44.62 |
| 52 Week High | $223.61 | $60.12 |
Technical Indicators
Market Signals| Indicator | PANW | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 44.69 | 44.58 |
| Support Level | $153.74 | $45.20 |
| Resistance Level | $205.60 | $49.01 |
| Average True Range (ATR) | 6.53 | 0.81 |
| MACD | 0.67 | 0.03 |
| Stochastic Oscillator | 52.68 | 20.59 |
Price Performance
Historical ComparisonAbout PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.